文献速递抗栓抗凝管理药物不良反应与药物警戒

依达赛珠单抗与andexanet alfa后弥散性血管内凝血:FAERS不成比例报告信号评估

Disseminated Intravascular Coagulation Following Idarucizumab and Andexanet Alfa: Assessment of a Signal of Disproportionate Reporting From the Food and Drugs Administration Adverse Event Reporting System (FAERS) Database.
PubMed 文献 · Drug Saf · 2026-03-22

基于FAERS 2004–2022年11,561,146份ICSRs进行不成比例分析,依达赛珠单抗和andexanet alfa分别有1463和399份报告。依达赛珠单抗-DIC的ROR为14.5(95%CI 8.0–26.3),andexanet alfa-DIC的ROR为19.4(95%CI 7.2–51.9),个案评估显示部分病例因果关系为「可能」。

要点

  • 依达赛珠单抗和andexanet alfa均检出与DIC不成比例报告信号。
  • 依达赛珠单抗-DIC的ROR为14.5(95%CI 8.0–26.3)。
  • andexanet alfa-DIC的ROR为19.4(95%CI 7.2–51.9)。

核心结论

  • FAERS不成比例分析提示依达赛珠单抗与DIC、andexanet alfa与DIC存在关联信号。
  • 个案评估虽受适应证偏倚限制,但给药后1天内发生的病例因果关系仍可能。

研究设计与样本

  • 基于FAERS 2004–2022年ICSRs的病例/非病例不成比例分析。
  • 共分析11,561,146份ICSRs,依达赛珠单抗和andexanet alfa分别有1463和399份疑似药物报告。
  • 对434个Preferred Terms计算ROR及95%CI,信号定义为≥3份ICSR且ROR下限>1。
  • 对意外且生物学合理的药物-事件对进行个案评估,采用WHO-UMC因果关系评估系统。

主要发现

  • 依达赛珠单抗获得21个SDR,andexanet alfa获得19个SDR。
  • 依达赛珠单抗-DIC的ROR为14.5(95%CI 8.0–26.3),andexanet alfa-DIC的ROR为19.4(95%CI 7.2–51.9)。
  • 依达赛珠单抗9例死亡,andexanet alfa 4例死亡。
  • 依达赛珠单抗5例、andexanet alfa 3例因果关系判定为「可能」,均发生于给药后1天内。

关键数值与推荐

  • SDR定义:药物-事件对报告于≥3份ICSR且ROR的95%CI下限>1。
  • 依达赛珠单抗-DIC:ROR 14.5(95%CI 8.0–26.3)。
  • andexanet alfa-DIC:ROR 19.4(95%CI 7.2–51.9)。

临床怎么用

  • 使用DOAC逆转剂后应密切随访高风险患者,以及时发现凝血病征象。
  • 观察到此类不良事件应及时报告至相关药物警戒系统。

局限性

  • 个案评估受适应证偏倚的内在限制。
  • 部分ICSRs缺乏个案叙述,因果评估受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idarucizumab and andexanet alfa are licensed for the emergency reversal of the antithrombotic effect of direct oral anticoagulants (DOAC). Given their recent commercialization and rare use in clinical practice, current evidence on rare thromboembolic adverse events following idarucizumab or andexanet alfa administration is insufficient to draw definitive conclusions. OBJECTIVE: The aim of this study was to perform a signal detection analysis based on data from a large spontaneous reporting database to identify possible safety signals concerning rare, serious and unexpected thromboembolic events reported following the administration of idarucizumab and andexanet alfa, respectively. METHODS: A disproportionality analysis was performed based on Individual Case Safety Reports (ICSRs) submitted from any US or non-US country between 2004 and 2022 to the FDA Adverse Event Reporting System (FAERS). A case/non-case approach was applied: cases were ICSRs containing the event of interest, non-cases were the remaining reports. The odds of exposure to idarucizumab and andexanet alfa, respectively, in cases versus non-cases was measured. Reporting odds ratio (ROR) and 95% confidence intervals (95% CI) were calculated for 434 Preferred Terms from three relevant sub-standardized MedDRA® queries. Signals of disproportionate reporting (SDR) were drug-event pairs reported in three or more ICSRs, with the lower 95% CI of RORs > 1. SDRs corresponding to unexpected and biologically plausible drug-event pairs were selected for further evaluation through a case-by-case assessment. Original ICSRs, including case narratives, were obtained from the FDA. The WHO-UMC system for standardized case causality assessment was used to guide and classify the expert-based judgement of individual cases. RESULTS: A total of 11,561,146 ICSRs submitted to FAERS between 2004 and 2022 were analysed. Idarucizumab and andexanet alfa were listed as suspected drugs in 1463 and 399 reports, respectively. A total of 21 SDRs for idarucizumab and 19 for andexanet alfa were obtained. Eleven ICSRs containing the drug-event pair idarucizumab-disseminated intravascular coagulation (DIC) (ROR 14.5; 95% CI 8.0-26.3) and four containing andexanet-alfa-DIC (ROR 19.4; 95% CI 7.2-51.9) were selected for case-by-case assessment. Two additional andexanet-alfa-DIC ICSRs submitted in 2023 were identified using the FAERS Public Dashboard, although one was a duplicate. Nine of the 11 for idarucizumab and four of the five for andexanet alfa were original ICSRs with a case narrative available. Age was reported in ten idarucizumab cases (mean 79 years) and four andexanet alfa cases (mean 71 years). Nine idarucizumab cases and four andexanet alfa cases were fatal. Causality was judged 'possible' for five idarucizumab cases and three andexanet alfa cases which occurred within 1 day from administration. The remaining ICSRs were classified as 'unlikely' or 'conditional/unclassifiable'. CONCLUSIONS: The disproportionality analysis of the FAERS allowed us to highlight the associations between idarucizumab-DIC and andexanet-alfa-DIC, which might otherwise have remained unobserved due to the rarity of DIC and the low utilization of idarucizumab and andexanet alfa. Although the case-by-case evaluation was limited by the intrinsic indication bias, a causal link remained possible in those cases that occurred soon after administration. Since DIC is a life-threatening and often fatal condition, further investigation is warranted while close follow-up of high-risk patients may be considered to promptly detect any sign of coagulopathy following the administration of DOAC reversal agents. Any such observed adverse events should be reported to the relevant pharmacovigilance system in a timely manner.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Roberto G, Parmeggiani L, Flaccavento A, et al. Disseminated Intravascular Coagulation Following Idarucizumab and Andexanet Alfa: Assessment of a Signal of Disproportionate Reporting From the Food and Drugs Administration Adverse Event Reporting System (FAERS) Database. Drug Saf. 2026. PMID: 41865355. doi:10.1007/s40264-026-01648-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。